Durvalumab - CaLiGraph

CaLiGraph

Property	Value
rdf:type	owl:NamedIndividual Monoclonal antibody Orphan drug Therapeutic monoclonal antibody Experimental cancer drug AstraZeneca brand Drug granted breakthrough therapy designation
rdfs:label	Durvalumab
owl:sameAs	dbr:Durvalumab
prov:wasDerivedFrom	http://en.wikipedia.org/wiki/Category:Experimental_cancer_drugs http://en.wikipedia.org/wiki/Category:Orphan_drugs http://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies http://en.wikipedia.org/wiki/Category:Monoclonal_antibodies http://en.wikipedia.org/wiki/Monoclonal_antibody_therapy http://en.wikipedia.org/wiki/List_of_drugs_granted_breakthrough_therapy_designation http://en.wikipedia.org/wiki/Category:AstraZeneca_brands http://en.wikipedia.org/wiki/Cancer_immunotherapy http://en.wikipedia.org/wiki/Checkpoint_inhibitor http://en.wikipedia.org/wiki/MedImmune http://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors
skos:prefLabel	Durvalumab
skos:altLabel	durvalumab
clgo:alternativeName	Imfinzi
clgo:casNumber	1428935-60-7
clgo:drugbank	DB11714
clgo:fdaUniiCode	28X28X9OKV
clgo:kegg	D10808
clgo:medlinePlus	a617030
clgo:pubchem	249565666

About: clgr:Durvalumab